European Research Spends on Errors

An estimated 360 million Euros from the coffers of EU research funding was spent mistakenly; auditors blame overly complicated funding rules.

Written byEdyta Zielinska
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Wikimedia, Julien JorgePotentially half of all research projects funded by Europe are making mistakes in the costs they claim, according to a recent audit of 2011 expenses. The auditors say that the errors are not likely to be fraudulent, but rather caused by the complex rules and regulations over how money can be spent within the EU’s Framework Programs, through which research under specified goals is funded.

The auditors found one project which claimed 366,891 Euros in overhead costs, 180,670 Euros of which was inaccurately claimed. A portion of that money was recovered by the European Commission’s own estimate of the overage.

“The numbers may seem alarming at first glance but the overall impact is small,” Michael Jennings, a spokesman for the European Commission’s research section told Nature. Furthermore, such budgetary problems are far from unique among European budgets, one member of a team of European auditors told Nature.

The Framework Programs that have caused so much confusion are to be succeeded in 2014 by a new program called Horizon 2020. “The radical simplification under Horizon 2020 should make people's lives easier and reduce error, while still ensuring good oversight and control,” ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies